Antibodies Against the Plasmodium vivax Apical Membrane Antigen 1 From the Belem Strain Share Common Epitopes Among Other Worldwide Variants
Autor: | Gustavo Henrique Goulart Trossini, Renan Augusto Gomes, Katia Sanches Françoso, Maristela G Cunha, Ana Caroline Barbosa França, Eduardo Lani Volpe da Silveira, Irene S. Soares, Rodolfo F. Marques, Marinete Marins Póvoa |
---|---|
Jazyk: | angličtina |
Rok vydání: | 2021 |
Předmět: |
0301 basic medicine
Microbiology (medical) 030231 tropical medicine Immunology Plasmodium vivax malaria lcsh:QR1-502 Microbiology Plasmodium Epitope lcsh:Microbiology polymorphism Polimorfismo Gen?tico 03 medical and health sciences 0302 clinical medicine Antigen vaccine parasitic diseases medicine Plasmodium vivax / parasitologia Apical membrane antigen 1 biology biology.organism_classification medicine.disease Virology PROTEÍNAS RECOMBINANTES Vacinas Antimal?ricas 030104 developmental biology Infectious Diseases Mal?ria Vivax / patologia Polyclonal antibodies apical membrane antigen 1 Ant?genos biology.protein Antibody geographic locations Malaria |
Zdroj: | Frontiers in Cellular and Infection Microbiology, Vol 11 (2021) Repositório Institucional da USP (Biblioteca Digital da Produção Intelectual) Universidade de São Paulo (USP) instacron:USP Repositório Digital do Instituto Evandro Chagas (Patuá) Instituto Evandro Chagas (IEC) instacron:IEC |
ISSN: | 2235-2988 |
DOI: | 10.3389/fcimb.2021.616230/full |
Popis: | This work was supported by grants from Fundac??o de Amparo ? Pesquisa do Estado de S?o Paulo (FAPESP 2012/ 13032-5 and 2016/50108-0), Instituto Nacional de Cie?ncia e Tecnologia de Vacinas (INCTV), National Counsel of Technological and Scientific Development (CNPq ? 555.654/2009-5), and Para? State Research Foundation (FAPESPA ? ICAAF 005/2011). University of S?o Paulo. School of Pharmaceutical Sciences, Department of Clinical and Toxicological Analyses. S?o Paulo, SP, Brazil. University of S?o Paulo. School of Pharmaceutical Sciences, Department of Clinical and Toxicological Analyses. S?o Paulo, SP, Brazil. University of S?o Paulo. School of Pharmaceutical Sciences, Department of Clinical and Toxicological Analyses. S?o Paulo, SP, Brazil. University of S?o Paulo. School of Pharmaceutical Sciences. Department of Pharmacy. S?o Paulo, SP, Brazil. University of S?o Paulo. School of Pharmaceutical Sciences. Department of Pharmacy. S?o Paulo, SP, Brazil. Minist?rio da Sa?de. Secretaria de Vigil?ncia em Sa?de. Instituto Evandro Chagas. Ananindeua, PA, Brasil. Universidade Federal do Par?. Instituto de Ci?ncias Biol?gicas. Bel?m, PA, Brazil. University of S?o Paulo. School of Pharmaceutical Sciences, Department of Clinical and Toxicological Analyses. S?o Paulo, SP, Brazil. University of S?o Paulo. School of Pharmaceutical Sciences, Department of Clinical and Toxicological Analyses. S?o Paulo, SP, Brazil. Malaria is a human parasitic disease distributed in many tropical countries and caused by various Plasmodium species. Plasmodium vivax has the largest geographical distribution of the Plasmodium species and is predominant in the Americas, including Brazil. Only a small number of P. vivax vaccine formulations have successfully reached clinical trials relative to their P. falciparum counterparts. One of the candidate antigens for a blood-stage P. vivax vaccine is apical membrane antigen 1 (PvAMA-1). Due to the worldwide distribution of Plasmodium parasites, a high degree of variability has been detected in this antigen sequence, representing a considerable challenge to the development of a universal vaccine against malaria. In this study, we evaluated how PvAMA-1 polymorphisms influence vaccine-derived immune responses in P. vivax malaria. To this end, we expressed 9 recombinant protein representatives of different PvAMA-1 allelic variants in the yeast Pichia pastoris: Belem, Chesson I, Sal-1, Indonesia XIX, SK0814, TC103, PNG_05_ESP, PNG_62_MU, and PNG_68_MAS. After protein expression and purification, we evaluated the breadth of the immune responses derived from malaria-exposed individuals from the Amazon region. From 611 serum samples of malaria-exposed individuals, 53.68% of them reacted against the PvAMA-1 Belem through ELISA. Positive samples were further tested against recombinant proteins representing the other PvAMA-1 allelic variants. Whereas Sal-1, Chesson I and SK0814 variants were highly recognized by tested serum samples, Indonesia XIX, TC103, PNG_05_ESP, PNG_62_MU, and PNG_68_MAS were only slightly recognized. Moreover, polyclonal sera derived from C57BL/6 mice immunized with the PvAMA-1 Belem protein predominantly recognized Belem, Sal-1, Chesson I, SK0814, and Indonesia XIX through ELISA. Last, ELISA-based competition assays demonstrated that a previous interaction between anti-Belem polyclonal serum and Sal-1, Chesson I, SK0814, or Indonesia XIX proteins could further inhibit antibody binding to the Belem variant. Our human and mouse data suggest the presence of common epitopes or cross-reactivity between Belem, Sal-1, Chesson I, and SK0814 variants. Although the PvAMA-1 Belem variant induces strain-transcendent antibodies, PvAMA-1 variants from Thailand and Papua New Guinea may need to be included in a universal vaccine formulation to achieve protection against P. vivax malaria. |
Databáze: | OpenAIRE |
Externí odkaz: |